Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the ...

The rate of appropriate treatment suggestions was 86.6% for Claude3-Opus, 85.7% for GPT4-Turbo, and 75.0% for LLaMa3-70B. Artificial intelligence (AI) can accurately suggest appropriate adjuvant ...

During a live event, Matthew Galsky, MD discussed neoadjuvant and adjuvant options for a patient case including nivolumab or ...

Results from a meta-analysis suggest patients with resectable dMMR/MSI-H gastric cancer can forgo perioperative chemotherapy.

EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...

Imfinzi in combination with chemotherapy has been approved in the European Union, EU, for the treatment of adults with ...

A new study links changes in frailty, a measure of decreased physiological capacity that leads to fatigue, slow walking, muscle weakness, physical inactivity, and weight loss, to five-year survival ...

Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.

Bristol Myers BMY announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has recommended approval of Opdivo (nivolumab) for another ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer.

Toxicity related to the systematic delivery of IL-12, a well-known and widely researched anti-tumor cytokine, has limited its ...